ReWalk Robotics (RWLK) Projects Prelim. FY18 Revenue of Approx. $6.5M

ReWalk Robotics Ltd. (NASDAQ: RWLK) today announced preliminary, unaudited revenue for the fiscal year ended December 31, 2018.

On a preliminary basis, based on the information currently available, for the fiscal year ended December 31, 2018, the Company expects that total revenue for the year will be approximately $6.5 million.

As the Company has not completed its year-end fiscal close and the audit of its 2018 financial statements is not complete, the revenue presented in this press release is estimated and preliminary, and therefore, subject to year-end closing adjustments and may change.

“Although we have seen progress in Germany, we did not achieve our anticipated results in the U.S. in the fourth quarter of 2018. We continue to believe there is a solid market for our ReWalk exoskeleton for SCI patients and look forward to continuing to advance our ReStore system for stroke patients. With our clinical study accrual now completed, we plan to finalize our ReStore submission to the U.S Food and Drug Administration shortly,” said Larry Jasinski, Chief Executive Officer of ReWalk. “We remain confident that we are on the right path to meet our long-term goals.”

You May Also Be Interested In

• 3 E Network CEO outlines robotics strategy focused on edge AI chips
• Lyell Immunopharma reports safety data for lymphoma CAR T-cell therapy
• Swarmer chairman outlines expansion strategy beyond drone software